Biology Reference
In-Depth Information
Francis SH, Corbin JD (2005) Phosphodiesterase-5 inhibition: the molecular biology of erectile
function and dysfunction. Urol Clin North Am 32:419-429, vi
Francis SH, Corbin JD (2009) Phosphodiesterase-5. In: Bradshaw RA, Dennis EA (eds) Handbook
of cell signaling, vol 2, 2nd edn. Academic, Oxford, pp 1439-1444
Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD (1994) Zinc interactions and conserved
motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydro-
lase. J Biol Chem 269:22477-22480
Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA, Corbin JD (2006) Phosphodies-
terase-5: molecular characteristics relating to structure, function, and regulation. In: Beavo
SHF JA, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC
Press, Boca Raton, pp 131-164
Francis SH, Morris GZ, Corbin JD (2008) Molecular mechanisms that could contribute to
prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20:
333-342
Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1
potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
Mol Pharmacol 54:962-967
Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH (1999) Effects of
the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and
phosphodiesterase activity. Br J Pharmacol 127:195-203
Giembycz MA (2006) Reinventing the wheel: nonselective phosphodiesterase inhibitors for
chronic inflammatory diseases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide
phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 649-665
Gopal VK, Francis SH, Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A
potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur
J Biochem 268:3304-3312
Goraya TA, Cooper DM (2005) Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current
perspectives. Cell Signal 17:789-797
Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE (2006) cAMP is a ligand for the
tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain
of phosphodiesterase 11. J Biol Chem 281:2841-2846
Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators
of phosphodiesterase 4. Francis SH, Conti M, HouslayMD (eds) Phosphodiesterases as drug
targets. Springer, Heidelberg
Han P, Sonati P, Rubin C, Michaeli T (2006) PDE7A1, a cAMP-specific phosphodiesterase, inhibits
cAMP-dependent protein kinase by a direct interaction with C. J Biol Chem 281:15050-15057
Handa N, Mizohata E, Kishishita S, Toyama M, Morita S, Uchikubo-Kamo T, Akasaka R, Omori K,
Kotera J, Terada T, ShirouzuM, Yokoyama S (2008) Crystal structure of the GAF-B domain from
human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 283:19657-19664
Hayes JS, Brunton LL, Brown JH, Reese JB, Mayer SE (1979) Hormonally specific expression of
cardiac protein kinase activity. Proc Natl Acad Sci USA 76:1570-1574
He F, Seryshev AB, Cowan CW, Wensel TG (2000) Multiple zinc binding sites in retinal rod
cGMP phosphodiesterase, PDE6alpha beta. J Biol Chem 275:20572-20577
Heikaus CC, Stout JR, Sekharan MR, Eakin CM, Rajagopal P, Brzovic PS, Beavo JA, Klevit RE
(2008) Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights
into nucleotide specificity, dimerization, and cGMP-dependent conformational change. J Biol
Chem 283:22749-22759
Hirano T, Yamagata T, Gohda M, Yamagata Y, Ichikawa T, Yanagisawa S, Ueshima K, Akamatsu
K, Nakanishi M, Matsunaga K, Minakata Y, Ichinose M (2006) Inhibition of reactive nitrogen
specids production in COPD airways: comparison between inhaled corticosteroid and oral
theophylline. Thorax 61:761-766
Hoffmann R, Wilkinson IR, McCallum JF, Engels P, Houslay MD (1998) cAMP-specific phos-
phodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition
